Pacira BioSciences (PCRX) Stock Price, News & Analysis

Company Overview

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies. Pacira primarily serves healthcare professionals and institutions in the United States and has pursued international commercialization through partnerships and licensing arrangements.

Key Stats

• Today's Range: $36.30 to $36.35
• 50-Day Range: $23.00 to $36.39
• 52-Week Range: $18.80 to $36.46
• Volume: 2.22 million shs
• Average Volume: 2.26 million shs
• Market Capitalization: $1.45 billion
• P/E Ratio: 23.30
• Dividend Yield: N/A
• Price Target: $33.33
• Consensus Rating: Hold

Pacira BioSciences Stock Analysis - MarketRank™

Pacira BioSciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 733rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Pacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 9 hold ratings, and 1 sell rating.

Downside Risk

Pacira BioSciences has a consensus price target of $33.33, representing about 8.2% downside from its current price of $36.31.

Amount of Analyst Coverage

Pacira BioSciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 27.42%

Earnings Growth

Earnings for Pacira BioSciences are expected to grow by 27.42% in the coming year, from $1.86 to $2.37 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pacira BioSciences is 23.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.60.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pacira BioSciences is 23.30, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 193.11.

Price to Book Value per Share Ratio

Pacira BioSciences has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.65% of the float of Pacira BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Pacira BioSciences has a short interest ratio ("days to cover") of 15.05, which indicates bearish sentiment.

Change versus previous month

Short interest in Pacira BioSciences has recently increased by 6.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pacira BioSciences does not currently pay a dividend.

Dividend Growth

Pacira BioSciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.18

News Sentiment

Pacira BioSciences has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 53 news articles for Pacira BioSciences this week, compared to 5 articles on an average week.

Search Interest

2 people have searched for PCRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $288,539.00 in company stock.

Percentage Held by Insiders

6.40% of the stock of Pacira BioSciences is held by insiders.

Percentage Held by Institutions

99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PCRX
• CIK: 1396814
• Web: www.pacira.com
• Phone: (813) 553-6680
• Fax: 302-655-5049
• Employees: 829
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Pacira BioSciences: $33.33
• High Price Target: $36.50
• Low Price Target: $25.00
• Potential Upside/Downside: -8.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.35
• Trailing P/E Ratio: 23.30
• Forward P/E Ratio: 19.52
• P/E Growth: N/A
• Net Income: $7.03 million
• Net Margins: 1.96%
• Pretax Margin: 2.37%
• Return on Equity: 9.68%
• Return on Assets: 5.30%

Debt

• Debt-to-Equity Ratio: 0.54
• Current Ratio: 5.04
• Quick Ratio: 3.94

Sales & Book Value

• Annual Sales: $726.41 million
• Price / Sales: 1.99
• Cash Flow: $3.85 per share
• Price / Cash Flow: 9.42
• Book Value: $16.11 per share
• Price / Book: 2.25

Miscellaneous

• Outstanding Shares: 39,860,000
• Free Float: 37,311,000
• Market Cap: $1.45 billion
• Optionable: Optionable
• Beta: 0.25